Dr. Daria Chestnykh

● Managed 8 research projects in psychopharmacology, resulting in the preclinical characterisation of 5 novel pharmaceutical compounds that contributed to cutting-edge treatments for psychiatric disorders ● Designed and conducted 25+ translational experiments, producing comprehensive datasets; analysed, interpreted, and presented findings within cross-functional international teams ● Uncovered a novel mechanism of action for antipsychotic drugs, identifying new sphingolipid targets for pharmacological therapies ● Presented findings at 4 major international conferences, including FENS 2024 and EBPS 2023, and contributed to 5 publications in peer-reviewed journals, building productive collaborations ● Optimised experimental workflows, reducing average study completion time by 20%

● Coordinated the planning and execution 2 Phase I-II clinical trials (vaccines), achieving 100% regulatory compliance with local and international standards ● Oversaw clinical trial timelines, budgets, and milestones, delivering 100% on-time project execution aligned with company goals ● Managed to prepare and communicate essential clinical trial documents, ensuring seamless operations and logistics for investigational products to CROs and sites ● Improved communication efficiency by 25% through the implementation of new collaboration strategies and tools ● Conducted quality control processes in collaboration with CROs, leading to a 20% reduction in deviations and ensuring 100% GCP/ICH compliance ● Administered planning and execution of preclinical studies for 5 projects (vaccines and diagnostics), fully complied with local and international regulations (GLP/ICH, EMEA guidelines) and secured CTA approval within the projects' scope, timeline and budget

● Developed 10+ preclinical study programs for Originator and Generic drugs (small molecules), ensuring GLP/ICH guidelines compliance within approved timelines, quality standards and budgets, contributing to successful regulatory submissions in a fast-paced environment at national and international level ● Managed 12 complex projects covering CNS, Cough&Cold, Gastroenterology, and Antibacterial therapeutic groups, securing 100% regulatory approvals and clinical trials authorization. ● Collaborated with interdisciplinary teams, such as Project Management, R&D, Clinical Trials, Regulatory Affairs and Marketing, for strategic project development, portfolio and product lifecycle management. ● Proactively identified and escalated potential operational issues with a detail-oriented approach, and implemented accurate evaluation projects and process improvement initiatives, resulting in timely resolution and 100% successful study accomplishments. ● Contributed to cross-functional team meetings in the evaluating of the product portfolio, analysing scientific background for novel indications and therapeutic modalities ● Provided scientific literature reviews, science-based materials and consulting support for multifunctional teams and stakeholders regarding strategic directions and drug development plans.

● Optimised the timelines and quality of preclinical studies by 30% by initiating collaboration with 10 new EU, USA, China, and Russia research centres and establishing strong relationships with partner CROs and external vendors. ● Enhanced research quality by reviewing and editing Study protocols and reports, and conducting regular Sponsor oversight visits, resulting in a 15% decrease in protocol deviations and a 25% increase in data accuracy. ● Designed, administered and controlled 25+ preclinical studies, including GLP and non-GLP studies, toxicology, pharmacology, pharmacokinetics and early stage proof-of-concept studies, oversaw the preparation of study protocols, amendments, deviations and reports, collaborating with CROs and AROs resulting in smooth approval of Module 4 of CTD. ● Administered planning, execution and tracking of pre-clinical study procedures, including data systems and resource management, within defined timelines, budgets and quality requirements.

● Administered invoices and accruals with 100% budget compliance, ensuring financial transparency ● Collaborated with global CROs to develop study-related documents and monitored seamless execution, adhering to GLP standards ● Introduced new sponsor oversight practices, reducing reporting inconsistencies by 10%

● Executed in-house preclinical studies for 5 biosimilar insulins, resulting in clinical trial approvals and fulfilment of government contracts ● Evaluated novel therapeutic compounds for strategic alignment with company goals ● Optimised internal laboratory workflows, reducing sample processing times by 15%

PhD Thesis: "Sphingolipid neurobiology of schizophrenia and its treatment"

Master's Thesis: "Establishment of an animal model of endogenous depression using chronic unpredictable mild stress"

Bachelor Thesis: "The effects of prostaglandin F2alfa on maternal behaviour in mice"